logo-loader
ImmuPharma PLC

Immupharma PLC - Notice of AGM & Posting of Annual Report

RNS Number : 4022Q
Immupharma PLC
06 June 2018
 

 

 

6 June 2018

 

This announcement contains inside information for the purposes of Article 7 of Regulation (EU) 596/2014.

 

 

 

ANNUAL REPORT AND ACCOUNTS POSTED TO SHAREHOLDERS
 

NOTICE OF ANNUAL GENERAL MEETING ON 28 JUNE 2018 @ 10.30 AM

 

VENUE: SKY LIGHT CITY TOWER, 50 BASINGHALL STREET, LONDON, EC2

 

ImmuPharma PLC (LSE:IMM), ("ImmuPharma" or the "Company"), the specialist drug discovery and development company confirms that the Annual Report and Accounts for the year ended 31 December 2017 has been posted to shareholders.

This report includes the 'Annual Report of the Annual General Meeting' ('AGM') as well as the 'Notice of the 2018 AGM', which will be available later today, in electronic form, for download on the Company's website www.immupharma.org.

ImmuPharma's AGM will be held on Thursday 28 June at 10:30am at Sky Light City Tower, 50 Basinghall Street, EC2V 5DE. 

-Ends-

 

 

 

For further information please contact:

 

ImmuPharma plc (www.immupharma.co.uk)

+ 44 (0) 20 7152 4080

Tim McCarthy, Chairman

 

Lisa Baderoon, Head of Investor Relations

Twitter: @immupharma

 

+ 44 (0) 7721 413496

 

 

 

 

Northland Capital Partners Limited (NOMAD & Joint Broker)

David Hignell, Dugald Carlean, Jamie Spotswood, Corporate Finance

Rob Rees, Corporate Broking

 

 

+44 (0)20 3861 6625

 

 

 

 

 

 

 

 

Bryan, Garnier & Co. (Joint Broker)                                                                                          +44 (0)20 7332 2500

Phil Walker, Corporate Finance

Dominic Wilson, Sales

 

 

         

 


This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
 
END
 
 
NOALLFSERAIEIIT
NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of...

FOR OUR FULL DISCLAIMER CLICK HERE

ImmuPharma chairman more optimistic on results for its Lupuzor drug

Tim McCarthy, chairman of ImmuPharma PLC (LON:IMM) tells Proactive that there is a strong indication that in certain populations of lupus patients, its Lupuzor drug works very effectively.  McCarthy was talking after a deeper dive into the data generated by its phase III clinical trial of...

on 30/5/18

2 min read